The Interaction of Coagulation and Inflammation

  • Bruce D. Spiess
Part of the Developments in Critical Care Medicine and Anesthesiology book series (DCCA, volume 31)


Coagulation function has often been viewed by clinicians as a protein mediated process cascading from one reaction to the next with an eventual outcome of solid clot. This view has been fostered by medical school teaching that has focused upon the coagulation cascades. The effects of platelet numbers and platelet function may be less well understood and monitored. The complexity of coagulation and its many nuances can be daunting.


Plasminogen Activator Cardiopulmonary Bypass Plasminogen Activator Inhibitor Inflammatory System Minogen Activator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Essell JH, Martin TJ, Salinas J, et al. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vase Anesth 7:410–415, 1993CrossRefGoogle Scholar
  2. 2.
    Gertler JP, Abbott WM. Prothrombotic and fibrinolytic function of normal and perturbed endothelium. J Surg Res 52:89–95, 1992PubMedCrossRefGoogle Scholar
  3. 3.
    Eisenberg PR, ed. Endothelial cell mediators of thrombosis and fibrinolysis. Coronary Artery Disease. 2:129–166, 1991CrossRefGoogle Scholar
  4. 4.
    Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743–4746, 1989PubMedGoogle Scholar
  5. 5.
    Spiess BD. Perioperative coagulation concerns: function, monitoring and therapy. Clinical Anesthesia Updates 4:1–16, 1993Google Scholar
  6. 6.
    Mollace V, Salvemini D, Sessa WC, Vane JR. Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by Captopril and reduced thiols. J Pharmacol Exp Ther 258:820–823, 1991PubMedGoogle Scholar
  7. 7.
    Lucore CL. Regulation of fibrinolysis by vascular endothelium. Coronary Artery Disease 2:157–166, 1991CrossRefGoogle Scholar
  8. 8.
    Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49:2533–2553, 1989PubMedGoogle Scholar
  9. 9.
    Van Hinsbergh VW, Binnema D, Scheffer MA, et al. Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis 7:389–400, 1987PubMedCrossRefGoogle Scholar
  10. 10.
    Butler J, Rocker GM, Westaby S. Inflammatory responses to cardiopulmonary bypass. Ann Thorac Surg 55:552–559, 1993PubMedCrossRefGoogle Scholar
  11. 11.
    Jansen NJ, VanOeveren W, Gu YJ, et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744–748, 1992PubMedCrossRefGoogle Scholar
  12. 12.
    Gu YJ, VanOeveren W, Boonstra PW, et al. Leukocyte activation with increased expression of CR3 receptors during cardiopulmonary bypass. Ann Thorac Surg 53:839–843, 1992PubMedCrossRefGoogle Scholar
  13. 13.
    Menasché P, Peynet J, Larivière J, et al. Does normothermia during cardiopulmonary bypass increase neutrophil-endothelium interactions? Circulation 90:II275–279, 1994PubMedGoogle Scholar
  14. 14.
    Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 69:11–25, 1992PubMedCrossRefGoogle Scholar
  15. 15.
    Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorol 12 myristate 13 acetate and tumor necrosis factor. J Biol Chem 264:20705–20713, 1989PubMedGoogle Scholar
  16. 16.
    Schleef RR, Bevilacqua MP, Sawdey M, et al. Cytokine activation of vascular endothelium. J Biol Chem 263:5797–5803, 1988PubMedGoogle Scholar
  17. 17.
    Gouin I, Lecompte T, Morel MC. In-vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation 85:935–941, 1992PubMedGoogle Scholar
  18. 18.
    Kowalski E, Kopec M, Wegrzynowicz Z. Influence of fibrinogen degredation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thromb Diatr Haemorr 10:406, 1963Google Scholar
  19. 19.
    VanHinsbergh VW. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis 18:307–327, 1988Google Scholar
  20. 20.
    Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin and histamine. J Lab Clin Med 109:97–104, 1987PubMedGoogle Scholar
  21. 21.
    Erickson L, Ginsberg MH, Loskutoff DJ. An inhibitor of plasminogen activator in platelets. Haemostasis 14:65, 1984Google Scholar
  22. 22.
    Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of radioimmunoassay and observations on its plasma concentration during venous occlusion after platelet aggregation. Blood 70:1645–1653, 1987PubMedGoogle Scholar
  23. 23.
    Kluft C, Verheijen JH, Jie AF, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue type plasminogen activator after trauma. Scand J Clin Lab Invest 45:605–610, 1985PubMedCrossRefGoogle Scholar
  24. 24.
    Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3–9, 1987PubMedCrossRefGoogle Scholar
  25. 25.
    Margaglione M, DiMinno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor −1 in patients with a history of ischemic stroke. Arterioscler Thromb 14:1741–1745, 1994PubMedCrossRefGoogle Scholar
  26. 26.
    Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. Arterioscl Thromb 13:1412–1417, 1993PubMedCrossRefGoogle Scholar
  27. 27.
    Eriksson B, Eriksson E, Gyzander E, et al. Deep vein thrombosis after total hip replacement—relationship to the fibrinolytic system. Acta Orthop Scand 60:159–163, 1989PubMedCrossRefGoogle Scholar
  28. 28.
    Larsson J, Risberg B. Fibrinolytic activity in human legs in tourniquet ischemia. Thromb Res 11:817–825, 1977PubMedCrossRefGoogle Scholar
  29. 29.
    Mellbring G, Dahlgren S, Reiz S, et al. Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. Thromb Res 32:575–584, 1983PubMedCrossRefGoogle Scholar
  30. 30.
    Andreotti F, Davies GJ, Hackett D, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 62:635–637, 1988PubMedCrossRefGoogle Scholar
  31. 31.
    Tanaka K, Takao M, Yaka I, et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 3:181–188, 1989PubMedCrossRefGoogle Scholar
  32. 32.
    Chandler WL, Fitch JCK, Wall MH, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. J Thromb Hemost (submitted) 1995.Google Scholar
  33. 33.
    Andreasson S, Smith L, Aasen AO, et al. Local pulmonary activation of proteolytic enzymes after Escherichia-coli-induced lung injury in sheep. Eur Surg Res 20:289–297, 1988PubMedCrossRefGoogle Scholar
  34. 34.
    Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105:957–963, 1987PubMedCrossRefGoogle Scholar
  35. 35.
    Marcus AJ. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism. Blood 76:1903–1907, 1990PubMedGoogle Scholar
  36. 36.
    Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 87:571–580, 1991PubMedCrossRefGoogle Scholar
  37. 37.
    Del Maschio A, Evangelista V, Rajtar G, et al. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 258:870–879, 1990Google Scholar
  38. 38.
    Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 255:720–722, 1975PubMedCrossRefGoogle Scholar
  39. 39.
    Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte platelet adhesion. Blood 79:1201–1205, 1992PubMedGoogle Scholar
  40. 40.
    Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 107:280–288, 1994PubMedGoogle Scholar
  41. 41.
    Simpson PJ, Todd RF III, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CDllb) that inhibits leukocyte adhesion. J Clin Invest 81:624–629, 1988PubMedCrossRefGoogle Scholar
  42. 42.
    Wallis WJ, Beatty PG, Ochs HD, Harlan JM. Human monocyte adherence to cultured vascular endothelium: monoclonal antibody-defined mechanisms. J Immunol 135:2323–2330, 1985PubMedGoogle Scholar
  43. 43.
    Wright SD, Weitz JI, Huang AJ, et al. Complement receptor type three (CDllb/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci 85:7734–7738, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Bruce D. Spiess

There are no affiliations available

Personalised recommendations